In a recent study, a small molecule γ-secretase inhibitor, BMS-906024, sensitized NSCLC cell lines to paclitaxel, and both drugs synergized preclinically by targeting the paclitaxel-induced increase in NOTCH1, especially in cell lines with a KRAS and BRAF wild-type background versus their mutant counterparts, in a TP53-dependent manner (100). Here, KRAS is linked to non-small cell lung carcinoma.